Answers are grounded in this paper and cite their sources.
The long-acting injectable antipsychotic aripiprazole lauroxil (AL) can be initiated in a single day using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg oral dose of aripiprazole. Treatment with AL initiated using ALNCD significantly improved symptoms of schizophrenia in a phase 3b study. The current study evaluated real-world treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia who initiated AL using ALNCD. This retrospective analysis used data from January 1, 2018, to December 31, 2022, derived from Komodo’s Healthcare Map™, an administrative claims database. Adults with schizophrenia who initiated AL using ALNCD and had continuous enrollment ≥ 6 months before (baseline) and after (follow-up) initiation were eligible. Treatment patterns were evaluated for 6 months after initiation. Inpatient admissions, emergency department (ED) visits, and outpatient visits were compared before and after AL initiation using ALNCD. Patients who initiated AL using ALNCD in this study (n = 1152) had a mean age of 38.4 years; 35.9% were female. For most patients, their first AL dose was 1064 mg (39.4%) or 882 mg (37.1%); 90.3% received their first AL injection along with ALNCD on the same day. A total of 898 (78.0%) patients subsequently received a second AL dose at any time during follow-up. Proportions of patients with all-cause, mental health (MH)-related, and schizophrenia-related inpatient admissions and ED visits significantly decreased between baseline and follow-up (all P < 0.001). Proportions of patients with all-cause, MH-related, and schizophrenia-related outpatient visits did not change, whereas the mean number of outpatient visits for each HCRU category increased significantly from baseline to follow-up (all P ≤ 0.007). Findings from this real-world study suggest that use of AL initiated with ALNCD results in significant declines in acute HCRU. The long-acting injectable antipsychotic medication aripiprazole lauroxil is effective for the treatment of schizophrenia in adults. Aripiprazole lauroxil can be started in a single day using a one-time injection of an initiation formulation of aripiprazole lauroxil (called ALNCD) and a one-time 30-mg oral dose of aripiprazole. In this study, we examined insurance claims data to determine whether adults with schizophrenia who initiated aripiprazole lauroxil treatment using ALNCD received both injections in a single day and whether they continued to take aripiprazole lauroxil after their first dose. We also evaluated changes in the use of healthcare services after initiating aripiprazole lauroxil treatment using ALNCD. We found that almost all of the patients who started aripiprazole lauroxil using ALNCD received both injections on the same day, and more than three-quarters of the patients later received a second aripiprazole lauroxil dose. Fewer people were hospitalized or had an emergency room visit in the 6 months after they began aripiprazole lauroxil treatment using ALNCD compared with the 6 months before they started aripiprazole lauroxil. On average, each patient had more regular outpatient doctor visits after they started aripiprazole lauroxil treatment.
No takes yet. Share an insight, caveat, or question.
Lauriello et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: